Related Experiment Video
Updated: Jan 23, 2026

Study of Protein-protein Interactions in Autophagy Research
Published on: September 9, 2017
Blocking transmembrane219 protein signaling inhibits autophagy and restores normal cell death
1Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, United States of America.
Abstract:
Autophagy plays a vital role in tumor therapy and survival of dormant tumor cells. Here we describe a novel function of a protein known as Transmembrane 219 (TM219) as an autophagy activator. TM219 is a small membrane protein expressed in all known human tissues except the thymus. We used biochemical approaches to identify calmodulin and calmodulin dependent protein kinase II as a part of TM219 protein complex. Then, we employed in vitro reconstitution system and fluorescence anisotropy to study the requirements of TM219 to bind calmodulin in vitro. We also used this system to study the effects of a synthetic peptide derived from the sequence of the short cytoplasmic tail of TM219 (SCTT) on calmodulin-TM219 receptor interactions. We conjugated SCTT peptide with a pH Low Insertion peptide (pHLIP) for optimal cellular delivery. We finally tested the effects of SCTT-pHLIP on triple negative human breast cancer cells in three dimension culture. Our data defined a novel function of TM219 protein and an efficient approach to inhibit it.
Insights
Researchers discovered Transmembrane 219 (TM219) protein activates autophagy, crucial for tumor cell survival. They developed a novel peptide (SCTT-pHLIP) to inhibit TM219, offering a new strategy for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Autophagy is critical for tumor therapy and dormant tumor cell survival.
- Transmembrane 219 (TM219) is a small membrane protein expressed in most human tissues.
- The role of TM219 in autophagy regulation was previously unknown.
Purpose of the Study:
- To elucidate the novel function of TM219 as an autophagy activator.
- To identify TM219 interacting partners, specifically calmodulin and calmodulin-dependent protein kinase II.
- To develop and test a peptide-based inhibitor of TM219 for potential cancer therapy.
Main Methods:
- Biochemical approaches to identify TM219 protein complex components.
- In vitro reconstitution and fluorescence anisotropy to study TM219-calmodulin interactions.
- Development of a synthetic peptide (SCTT) conjugated to pHLIP for cellular delivery and testing in triple-negative breast cancer cells.
Main Results:
- TM219 was identified as an autophagy activator.
- Calmodulin and calmodulin-dependent protein kinase II were found to be part of the TM219 protein complex.
- The SCTT-pHLIP peptide effectively inhibited TM219 function in triple-negative human breast cancer cells in 3D culture.
Conclusions:
- TM219 possesses a novel function as an autophagy activator.
- A synthetic peptide-based approach (SCTT-pHLIP) provides an efficient strategy to inhibit TM219.
- This discovery opens new avenues for targeting autophagy in cancer therapy.
Related Concept Videos
Restorative Care
What is Cell Signaling?
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Cell-surface Signaling
Autophagy
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...

